Johan Courjon

Dr. Johan Courjon

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Journal of Clinical Virology
Verified
Journal Article
Closed access
AMAnne De Monte
Anne De Monte
JCJohan Courjon
Johan Courjon
RARodolphe ANTY
Rodolphe ANTY
ECEric Cua
Eric Cua
ANAlissa Naqvi
Alissa Naqvi
VGValérie Giordanengo
Valérie Giordanengo

1 November 2019 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
ADAurélien Dinh
Aurélien Dinh
CDClara Duran
Clara Duran
PPPatricia Pavese
Patricia Pavese
LKLydie Khatchatourian
Lydie Khatchatourian
BMBoris Monnin
Boris Monnin
PWPierre Weyrich
Pierre Weyrich

5 December 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJohan Courjon
Johan Courjon
ALAdrien Lemaignen
Adrien Lemaignen
IGIdir Ghout
Idir Ghout
ATAudrey Therby
Audrey Therby
NBNadia Belmatoug
Nadia Belmatoug
DGDTS (Duration of Treatment for Spondylodiscitis) study group
DTS (Duration of Treatment for Spondylodiscitis) study group
The incidence of pyogenic vertebral osteomyelitis (PVO) has increased over the past two decades. One possible cause of this increase is the aging of the population, which results in more comorbidities in high income countries. To better characterize the clinical presentation and outcome of PVO in the elderly. We conducted a post-hoc analysis of a previously published trial that studied treatment duration in PVO and compared the presentation and outcomes according to age. Our analysis included 351 patients among whom 85 (24%) were 75-years-old or more. There were no significant differences in the socio-demographics of the patients. Neoplasia and chronic inflammatory diseases were more common in the older group: 34% vs. 19% (p = 0.021) and 9% versus 1% (p = 0.004), respectively. There were no significant differences in clinical and radiological presentations between the groups in terms of back pain (337/351, 97%), fever (182/351, 52%), PVO localization, neurological signs and epidural abscess. Associated infective endocarditis (IE) was more frequent in the older group (37% vs. 14%, p<0.001). Streptococci were more frequently involved in infections of older patients (29% vs. 14%, p = 0.003) in contrast to Staphylococcus aureus (31% vs. 45%, p = 0.03). Older patients displayed higher mortality rates at 1 year (21% vs. 3%, p<0.001) and more adverse events related to cardiorespiratory failure (10.6% vs. 3.8%, p = 0.025), but had similar quality of life among the survivors. During PVO, the clinical and radiological findings are similar in older patients. Global mortality rates are higher in older patients compared to younger patients, which could be explained by the increased frequency of neoplasia at diagnosis and higher prevalence of associated IE in the elderly.

15 October 2015 in Toxins
Verified
Journal Article
Open access
PDF file
JCJohan Courjon
Johan Courjon
PMPatrick Munro
Patrick Munro
BYBenito Yvonne
Benito Yvonne
OVOrane Visvikis
Orane Visvikis
CBCoralie Bouchiat
Coralie Bouchiat
ELEmmanuel Lemichez
Emmanuel Lemichez
It is crucial to define risk factors that contribute to host invasion by Staphylococcus aureus. Here, we demonstrate that the chromosomally encoded EDIN-B isoform from S. aureus contributes to the onset of bacteremia during the course of pneumonia. Deletion of edinB in a European lineage community-acquired methicillin resistant S. aureus (CA-MRSA) strain (ST80-MRSA-IV) dramatically decreased the frequency and magnitude of bacteremia in mice suffering from pneumonia. This deletion had no effect on the bacterial burden in both blood circulation and lung tissues. Re-expression of wild-type EDIN-B, unlike the catalytically inactive mutant EDIN-R185E, restored the invasive characteristics of ST80-MRSA-IV.

24 March 2015 in Dermatology
Verified
Journal Article
Closed access
PDF file
JCJohan Courjon
Johan Courjon
THThomas Hubiche
Thomas Hubiche
Nicolas DupinNicolas Dupin
Nicolas Dupin
Philippe GrangePhilippe Grange
Philippe Grange
PGPascal Del Giudice
Pascal Del Giudice
Background: The incidence of HIV-syphilis co-infection has risen since 2000, especially among men having sex with men (MSM). Syphilis reinfection can occur, but the clinical features of such events remain poorly characterized. Objective: To compare the cutaneous lesions seen with syphilis reinfections with those of first episodes in HIV-infected patients. Methods: In a cohort of HIV-infected patients, syphilis reinfection was established both clinically and biologically by evaluating changes in Venereal Disease Research Laboratory titers. Photographs and medical records were studied in order to determine the type of skin lesions and their quantification. Results: Among 533 HIV-infected patients, 42 (8%) experienced a first syphilis infection. Thirteen episodes of reinfection occurred in 12/42 (28%) patients, all MSM. In 78% of cases, reinfections were less symptomatic than first episodes. All patients presented classical syphilis lesions. Conclusions: We observed a high rate of reinfection, but with less severe skin manifestations during reinfection episodes.

19 May 2017 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
JCJohan Courjon
Johan Courjon
EDElisa Demonchy
Elisa Demonchy
NDNicolas Degand
Nicolas Degand
KRKarine Risso
Karine Risso
RRRaymond Ruimy
Raymond Ruimy
PRPierre-Marie Roger
Pierre-Marie Roger
Bacteremia of unknown origin (BUO) are associated with increased mortality compared to those with identified sources. Microbiological data of those patients could help to characterize an appropriate empirical antibiotic treatment before bloodcultures results are available during sepsis of unknown origin. Based on the dashboard of our ward that prospectively records several parameters from each hospitalization, we report 101 community-acquired BUO selected among 1989 bacteremic patients from July 2005 to April 2016, BUO being defined by the absence of clinical and paraclinical infectious focus and no other microbiological samples retrieving the bacteria isolated from blood cultures. The in-hospital mortality rate was 9%. We retrospectively tested two antibiotic associations: amoxicillin–clavulanic acid + gentamicin (AMC/GM) and 3rd generation cephalosporin + gentamicin (3GC/GM) considered as active if the causative bacteria was susceptible to at least one of the two drugs. The mean age was 71 years with 67% of male, 31 (31%) were immunocompromised and 52 (51%) had severe sepsis. Eleven patients had polymicrobial infections. The leading bacterial species involved were Escherichia coli 25/115 (22%), group D Streptococci 12/115 (10%), viridans Streptococci 12/115 (10%) and Staphylococcus aureus 11/115 (9%). AMC/GM displayed a higher rate of effectiveness compared to 3GC/GM: 100/101 (99%) vs 94/101 (93%) (p = 0.04): one Enterococcus faecium strain impaired the first association, Bacteroides spp. and Enterococcus spp. the second. In case of community-acquired sepsis of unknown origin, AMC + GM should be considered.